Today’s Market Movers: Alnylam Soars 18% While AstraZeneca Tanks — What Investors Need to Know

TLDR

• Alnylam Pharmaceuticals surged 18.4% in premarket trading, leading gains on Thursday
• AstraZeneca fell 9% after its heart drug trial failed to meet its primary endpoint
• Levi Strauss dropped 6% despite beating Q2 revenue estimates, citing tariff headwinds
• Ampco-Pittsburgh jumped 14% after reporting a 32% rise in H1 orders to $268M
• S&P 500 futures edged up 0.10% while Bitcoin climbed 0.65% to $62,627

---

Alnylam Pharmaceuticals led premarket gains on Thursday, rising 18.4%. BridgeBio Pharma was also up 14% in early trading.

Alnylam Pharmaceuticals, Inc., ALNY

Kulicke & Soffa Industries, Advanced Energy Industries, and Cerebras Systems each posted gains of at least 6%.

S&P 500 futures were up slightly at 0.10%. Dow Jones futures slipped 0.15%. The Cboe Volatility Index futures rose 3.99%.

Bitcoin added 0.65%, trading at $62,627. Gold futures were up 0.77% and Brent crude rose 0.82%.

The 10-Year Treasury yield moved to 4.593%. In the prior session, the S&P 500 fell 0.28% and the Dow dropped 1.09%.

AstraZeneca Falls After Heart Drug Trial Fails

AstraZeneca was the biggest loser of the day, down 9%. The drop came after its Phase 3 CARDIO-TTRansform trial for Wainua failed to meet its primary endpoint.

The trial tested the drug in patients with transthyretin-mediated amyloid cardiomyopathy. It did not show a meaningful improvement in cardiovascular mortality or recurrent cardiovascular events compared to placebo over 140 weeks.

AstraZeneca developed Wainua with Ionis Pharmaceuticals. Following the news, Ionis shares fell 17.8%.

Both companies said they will continue analyzing the data. Full results are expected to be presented at the European Society of Cardiology Congress in August.

Levi Strauss Beats Estimates But Warns on Tariffs

Levi Strauss dropped 6% despite reporting Q2 revenue of $1.56 billion, up 7.6% year over year. Adjusted earnings per share of $0.28 beat analyst estimates.

Direct-to-consumer sales grew 11% and gross margin expanded to 62.7%. The results were solid on paper.

However, investors focused on the company’s cautious full-year outlook. Levi’s EPS guidance midpoint of $1.49 came in below the $1.51 consensus.

The company is assuming 30% U.S. tariffs on Chinese imports and 20% tariffs on goods from the rest of the world remain in place through year-end.

Ampco-Pittsburgh Jumps on Strong Orders

Ampco-Pittsburgh jumped 14% after reporting that H1 2026 customer orders rose 32% year over year to $268 million.

Forged and cast engineered products orders rose 25% to $153 million. Air and liquid processing orders surged 42% to $116 million.

The company also said its Buffalo Air Handling unit secured the largest air handling equipment order in its history.

MDA Space fell 6% after announcing a roughly 70% stake acquisition in France-based CLS for €567 million. The company also launched a C$712 million equity offering, which investors saw as dilutive.

Markets in Asia were up overnight, with Japan’s Nikkei 225 rising 1.38% and China’s Shanghai Composite gaining 1.65%.